Swiss authorities grant product approval for Intercell's IXIARO
Vaccine to help prevent Japanese Encephalitis now available in Switzerland
The decision by the Swiss authorities represents another important milestone for the licensure process initiated for selected attractive market segments. Intercell's vaccine, which helps to prevent Japanese Encephalitis, has already been approved and launched in the USA, Europe, Canada and Australia.
"The Swissmedic approval is great news and another important step in the product's global reach", states Thomas Lingelbach, Chief Operating Officer of Intercell.
IXIARO® is a modern purified, inactivated vaccine for active immunization of adults against infections caused by the Japanese Encephalitis Virus. IXIARO®is manufactured at Intercell's proprietary manufacturing facility in Scotland using tissue culture rather than live organisms.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.